


MiniMed™ 740G System

With SmartGuard™ technology



MiniMed™ mobile app

Easily tracks sugar levels and notifies on smart phone if your patients are going high or low.

Care partners can also download the CareLink™ Connect app to stay in the know.



Accu-Chek® guide link blood glucose meter

Accurate test results from the blood glucose meter are sent wirelessly to the pump for quick sensor calibrations.



CareLink™ mobile app


Have your patients link their accounts remotely using their CareLink™ Personal username to get CareLink™ Vital Insights without having to upload them on site. Manage and share your data with personalised diabetes insights to power your therapy decisions.

Guardian™ Sensor 3

Continuous Glucose Monitoring (CGM) sensor measures sugar levels every 5 minutes, sending info to the pump.



Now with Bluetooth® connectivity



Can provide advanced protection from hypoglycaemia, compared to CSII therapy:¹


- 73% less hypoglycaemias
- 79% less time spent in hypoglycaemias
- 84% less severe hypoglycaemias
- Lower rate of nocturnal hypoglycaemias

Medtronic

MiniMed™ 740G System With SmartGuard™ technology

With MiniMed™ 740G system with SmartGuard™ technology, your patients could prevent over 80% of severe hypoglycemic events without a significant increase in hyperglycemia.^{1*} It can help reduce the frequency of both high and low sensor glucose values and help stabilize sensor glucose after resumption of insulin delivery.^{2*} Sensor-augmented insulin pump therapy with the threshold-suspend feature reduces nocturnal hypoglycemia.³ Most of SmartGuard™ technology predicted hypoglycaemic events did not reach the pre-set low limit.^{2*}

SmartGuard™ technology helps¹ prevent lows to give your patients more control



SmartGuard™ technology can significantly reduce the risk for hypoglycemia in pediatric Type 1 Diabetes patients without increasing HbA1c.⁵

REFERENCES

1. Choudhary P, et al. Hypoglycemia Prevention and User Acceptance of an Insulin Pump System with Predictive Low Glucose Management Diabetes Technol Ther. 2016; 18(5):288-291.
2. Zhong A, et al. Effectiveness of Automated Insulin Management Features of the Medtronic 640G Sensor-Augmented Insulin Pump. Diabetes Technol Ther. 2016; 18(10): 657-663.
3. Bergenstal RM, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. The New England Journal of Medicine 2013;369(3):224-232.
4. Bosi E, et al. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial. Lancet Diabetes Endocrinol 2019;7: 462-72.
5. Biester T, et al. "Let the Algorithm Do the Work": Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients. Diabetes Technol Ther. 2017; 19(3):173-182.

*MiniMed™ 740G and the MiniMed™ 640G system share the same therapy algorithm.

EMEA-IPT-2200097 © Medtronic 2022. All rights reserved. Medtronic and the Medtronic logo are trademarks of Medtronic™.

This material does not replace or supersede the instructions for use. It should not be considered the exclusive source of information, and should be used in conjunction with the User Guide. See the User Guide for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative.

ACCU-CHECK AND ACCU-CHEK GUIDE LINK are trademarks of Roche Diabetes Care.

Medtronic